Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jason Grebely

Showing results (311-320 of 368) with videos related to

Pageof 37
Sort By:
The Lancet. Gastroenterology & Hepatology|May 9, 2021
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort studyBehzad Hajarizadeh, Jason Grebely, Marianne Byrne, et al.
The Lancet. Global Health|March 30, 2023
Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic reviewLouisa Degenhardt, Paige Webb, Samantha Colledge-Frisby, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Hepatology (Baltimore, Md.)|January 18, 2013
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infectionJason Grebely, Jordan J Feld, Tanya Applegate, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 2019
Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C InfectionLouise Geddes, Jenny Iversen, Handan Wand, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 CollaborativeAryan Esmaeili, Ali Mirzazadeh, Meghan D Morris, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 19, 2017
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapseFrançois M J Lamoury, Angelica Soker, Danica Martinez, et al.
The International Journal on Drug Policy|January 11, 2016
Empfehlungen zur Hepatitis Versorgung bei DrogenkonsumierendenJason Grebely, Geert Robaeys, Philip Bruggmann, et al.
The International Journal on Drug Policy|June 22, 2017
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE studyHåvard Midgard, Behzad Hajarizadeh, Evan B Cunningham, et al.
The International Journal on Drug Policy|November 3, 2018
Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in AustraliaSahar Bajis, Lisa Maher, Carla Treloar, et al.
Pageof 37

Showing results (311-320 of 368) with videos related to

Sort By:
Pageof 37
The Lancet. Gastroenterology & Hepatology|May 9, 2021
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort studyBehzad Hajarizadeh, Jason Grebely, Marianne Byrne, et al.
The Lancet. Global Health|March 30, 2023
Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic reviewLouisa Degenhardt, Paige Webb, Samantha Colledge-Frisby, et al.
Open Forum Infectious Diseases|February 17, 2018
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 StudiesJason Grebely, Jordan J Feld, David Wyles, et al.
Hepatology (Baltimore, Md.)|January 18, 2013
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infectionJason Grebely, Jordan J Feld, Tanya Applegate, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 2019
Sex Discrepancies in the Protective Effect of Opioid Agonist Therapy on Incident Hepatitis C InfectionLouise Geddes, Jenny Iversen, Handan Wand, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
The Effect of Female Sex on Hepatitis C Incidence Among People Who Inject Drugs: Results From the International Multicohort InC3 CollaborativeAryan Esmaeili, Ali Mirzazadeh, Meghan D Morris, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|May 19, 2017
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapseFrançois M J Lamoury, Angelica Soker, Danica Martinez, et al.
The International Journal on Drug Policy|January 11, 2016
Empfehlungen zur Hepatitis Versorgung bei DrogenkonsumierendenJason Grebely, Geert Robaeys, Philip Bruggmann, et al.
The International Journal on Drug Policy|June 22, 2017
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE studyHåvard Midgard, Behzad Hajarizadeh, Evan B Cunningham, et al.
The International Journal on Drug Policy|November 3, 2018
Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in AustraliaSahar Bajis, Lisa Maher, Carla Treloar, et al.
Pageof 37